Table 1.
Baseline Characteristics of the Cohort
| Features | Group 1 (10–15 y Postvaccination) (n = 50) | Group 2 (16–20 y Postvaccination) (n = 50) | Group 3 (>20 y Postvaccination) (n = 59) | P Valuea |
|---|---|---|---|---|
| Age at visit, y, average ± SD | 41 ± 10 | 46 ± 9 | 54 ± 7 | <.0001 |
| Age at vaccination, y, average ± SD | 27 ± 11 | 28 ± 8 | 30 ± 7 | .11 |
| Sex, female | 34 (68%) | 36 (72%) | 48 (81%) | .26 |
| Race, white | 30 (60%) | 33 (66%) | 47 (80%) | .08 |
| BMI, kg/m2 | 26 ± 5 | 26 ± 5 | 28 ± 6 | .04 |
| Handled HBV samples | 23 (46%) | 20 (40%) | 35 (59%) | .36 |
| Needle-stick | 10 (20%) | 13 (26%) | 28 (47%) | .005 |
| Mucocutaneous contact | 7 (14%) | 3 (6%) | 5 (8%) | .39 |
| Household HBV contact | 1 (2%) | 2 (4%) | 0 (0%) | .33 |
| HBV exposure risk score | .14 | |||
| Low | 21 (42%) | 25 (50%) | 17 (29%) | |
| Intermediate | 13 (26%) | 10 (20%) | 13 (22%) | |
| High | 16 (32%) | 15 (30%) | 29 (49%) | |
| Anti-HBc positive | 2 (4%) | 1 (2%) | 1 (2%) | |
| Diabetes mellitus | 2 (4%) | 2 (4%) | 3 (5%) | .94 |
| Hypertension | 9 (18%) | 6 (12%) | 14 (24%) | .28 |
| Chronic kidney disease | 0 (0%) | 0 (0%) | 1 (1%) | .42 |
| Smoker, past or current | 8 (16%) | 6 (12%) | 19 (32%) | .02 |
| Alcohol use | 34 (68%) | 42 (84%) | 50 (85%) | .06 |
Data are presented as No. (%) unless otherwise specified.
Abbreviations: anti-HBc, antibody to hepatitis B core antigen; BMI, body mass index; HBV, hepatitis B virus; SD, standard deviation.
aP values were calculated by t test (continuous variables) and χ2 test (frequency and categorical variables).